The New York Times

The New York Times became a national conduit for the OxyContin story through Barry Meier’s reporting, first bringing a major drug-abuse investigation to its front page and later documenting Purdue Pharma’s criminal case and the people affected by the drug. The newspaper’s role in the account is not simply that of a distant observer: its editors received a corporate challenge to Meier’s coverage, while Meier continued to follow the story and witnessed its consequences in Appalachia.

Bringing a Regional Crisis to the Front Page

On February 9, 2001, Meier and a colleague reported from just north of Lee County, Virginia, on Operation OxyFest, a nine-month federal investigation that had led to what the account describes as the largest drug-abuse raid in Kentucky history. The article made a regional crisis visible to a national readership. The arrests did not consist only of conventional dealers: many of the 207 people caught were patients who had obtained pills from doctors described as overburdened, careless, or quietly willing to overprescribe. A federal prosecutor told Meier that authorities had not caught even half of those involved, an indication of how widespread the activity had become.

That report appeared as OxyContin abuse was spreading beyond the rural communities where it had first drawn sustained attention. By the summer of 2001, overdose deaths and drug-related crime were making news in places from Miami-Dade County to Bridgeport, Connecticut, while pills were also circulating at suburban teenage parties. The book presents the front-page investigation as one moment in a widening public account: the crisis was no longer confined to the backwoods or to local police and court reporting. The newspaper gave the expanding story national reach, although the account does not credit it alone with the broader press attention that followed.

Reporting Under Corporate Pressure

Meier’s engagement with the subject continued beyond the initial article. His 2003 book, Pain Killer, made him familiar with Purdue Pharma’s efforts to challenge his reporting. After he had read the book, John Brownlee, newly appointed as U.S. attorney, began investigating Purdue, though the investigation was not made public until 2005. The timing mattered to Meier’s experience at the newspaper: Purdue lawyer Howard Udell complained to the New York Times editors that the book gave Meier a financial interest in the paper’s continued reporting on OxyContin and argued that he should be removed from the subject.

Meier later recalled that Purdue’s objective was to stop him and suppress further coverage. The book says the newspaper’s public editor, Daniel Okrent, accepted the conflict-of-interest argument without knowing that Purdue was already under criminal investigation, a possibility Meier himself suspected. With two minor exceptions, Meier did not write about Purdue for the newspaper again for four years. The episode therefore marks a sharp separation between the importance of the story and the opportunity of this particular reporter to cover it: the coverage was challenged through the paper’s own editorial channels, and Meier’s reporting on Purdue paused even as the federal inquiry continued out of public view.

Returning to the Story in Abingdon

Meier returned to the OxyContin case as the executives faced court proceedings in Abingdon. He had interviewed Howard Udell, Paul Goldenheim, and Michael Friedman repeatedly in corporate offices and by telephone, but wanted to see their Appalachian reckoning in person. He had already traveled to Abingdon in May, when the men first appeared to enter guilty pleas. To make his presence a surprise, he arrived the night before, stayed at a motel outside town, and waited with a freelance photographer hired by the newspaper near the hotel, concealed between parked cars.

The account places that reporting against a courthouse where Judge James P. Jones had seen his docket overtaken by OxyContin-related crime. Jones ordered that the executives enter through the front door like everyone else. Meier watched from nearby; when he and the photographer stood up, the executives appeared startled. Goldenheim looked toward the camera, while Udell and Friedman quickly looked away. For Meier, the scene offered something his many interviews had not: an opportunity to observe the men as they arrived for a public reckoning rather than encounter them only in their professional settings. The reporting remained attentive to the difference between access to executives and the consequences of their company’s actions in the region.

Witness to the Memorial

At the sentencing hearing, the newspaper’s reporter was also present for a different kind of record. Before the hearing, parents of people who had died took turns reading names gathered from Ed Bisch’s online memorial. The printed list had grown to more than fifty pages. Their voices faltered as they read, and they managed to get through only ten pages before the hearing began. Meier stood to the side, witnessing a public memorial whose scale could not be contained within the time available before court proceedings.

The contrast gives the newspaper’s place in the narrative its particular weight. The front-page story had counted arrests and reported how much of the network remained beyond law enforcement’s reach; the later court coverage unfolded beside a list of the dead that kept growing. The New York Times appears both as a national platform capable of making a regional crisis legible and as an institution whose coverage could be contested from within. Through Meier’s reporting and presence in Abingdon, the paper connects the investigation of a drug supply to the families’ insistence that its human costs be publicly named.